When OxyContin went to market in 1996, sales reps from Purdue Pharma hit one point particularly hard: Compared to other prescription opioids, this new painkiller was believed to be less likely to be addictive or abused. But recently unsealed documents in this investigative episode shed light on how the maker of OxyContin seems to have relied more on focus groups than on scientific studies to create an aggressive and misleading marketing campaign that helped fuel the national opioid crisis. Welcome back to The Uncertain Hour. Where the things we fight the most about are the things we know the least about. Subscribe on your favorite podcast app.